Have you ever thought about taking part in a Medical Trial? By registering your details with MedTrials.co.uk, we are able to send your details directly to companies who are looking for volunteers to take part in their medical research studies.
Information about you is kept on a register that CROs, Pharmaceutical companies and Clinical Investigators can access to contact you regarding individual studies.
MedTrials.co.uk is a website that will put you in direct contact with Pharmaceutical Companies, CRO’s (Clinical Research Organisations) and Clinical Investigators that are running Phase I (1) and Phase II (2) clinical trials.
Medical trials are an integral part of the drug development process. Patient and volunteer participation is vital for continued medical research and these trials are carried out under strict regulations.
If at any point you feel that you have changed your mind and are no longer interested in undertaking a medical trial you can unsubscribe from our service. If you are already part way through a medical trial, speak to the Clinical Investigator and they will advise you of your options.
Clinical research companies often offer financial compensation for your time and expenses.
Using high-speed screening technology, researchers have identified 53 drugs – including some antihistamines and antidepressants – that may prevent Ebola from entering human cells. Go to Source
A new study shows that when added to chemotherapy, trastuzumab – commonly known as Herceptin – significantly improves long-term survival of HER2-positive breast cancer patients. Go to Source
Vectura Group plc has announced the publication in the European Respiratory Journal (ERJ) of a clinical study demonstrating positive results from its Phase IIb/III (Acti-AICS-001) clinical trial… Go to Source
A well-established and effective treatment for breast cancer, tamoxifen has now been shown to have long-term preventive benefits for women at high risk. Go to Source
UCB has announced the primary efficacy and safety data from the latest Phase 3 study evaluating brivaracetam (fixed doses of 100 and 200 mg/day with no up-titration) as adjunctive treatment in… Go to Source
Gilead Sciences, Inc. has announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and the safety profile for… Go to Source